Cambrex, a leading global contract development and manufacturing organization (CDMO), has today completed the sale of its Drug Product Business Unit to Wilmington, Delaware based Noramco. Cambrex’s Drug Product business provides product development, clinical and commercial manufacturing, and packaging from facilities in Mirabel, Québec, Canada and Whippany, New Jersey, USA. “The transaction announced today was the result of a strategic decision to focus on core areas of growth and investment,” said Cambrex CEO Thomas Loewald. “Looking forward, Cambrex will prioritize our drug substance and analytical testing portfolios, enabling our customers to develop and deliver therapeutic solutions for patients around the world.”
Read the full article: Cambrex Announces Sale of Drug Product Business Unit //
Source: https://www.prnewswire.com/news-releases/cambrex-announces-sale-of-drug-product-business-unit-301975025.html